PMID- 36647464
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230118
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Dec
TI  - Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in 
      extensive-stage small-cell lung cancer: a retrospective comparative cohort study.
PG  - 4925-4937
LID - 10.21037/jtd-22-1682 [doi]
AB  - BACKGROUND: Evidence from clinical research and meta-analyses have suggested that 
      programmed cell death 1 (PD-1) inhibitors and programmed cell death ligand 1 
      (PD-L1) inhibitors plus chemotherapy could achieve a significant survival benefit 
      for extensive-stage small-cell lung cancer (ES-SCLC) patients. However clinical 
      researches concerned about the comparation between the PD-1 and PD-L1 inhibitors 
      were relatively lacking. METHODS: We collected the data of ES-SCLC patients 
      treated with PD-1 inhibitors or PD-L1 inhibitors. The primary endpoints were 
      overall survival (OS) and progression-free survival (PFS). Secondary endpoint 
      included adverse events (AEs). RESULTS: The data of 221 ES-SCLC patients treated 
      with PD-1 (n=146) or PD-L1 inhibitors (n=75) between February 2017 and June 2020 
      were retrospectively collected. The median OS (mOS) and median PFS (mPFS) were 
      19.07 and 8.27 months, respectively, in patients treated with PD-1 inhibitors. In 
      the PD-L1 group, mOS has not been reached, and mPFS was 7.95 months. No 
      significant differences were observed between the 2 groups in OS [hazard ratio 
      (HR), 1.472; 95% confidence interval (CI), 0.847-2.220; P=0.198] and PFS (HR, 
      0.816; 95% CI, 0.577-1.155; P=0.251). The rates of patients showed AEs of any 
      grade treated with PD-1 or PD-L1 were 67.12% and 64.00%, with no significant 
      difference (P=0.642, chi(2)=0.216), >/=3 grade AEs occurred in 42 (28.76%) and 16 
      (21.33%) patients treated with PD-1 and PD-L1 inhibitors separately, also no 
      significant difference (P=0.234, chi(2)=1.415) was observed. According to subgroup 
      analysis, camrelizumab revealed a longer mPFS (15.17 months) compared with other 
      immune-checkpoint inhibitors (ICIs). PD-1 and PD-L1 inhibitors revealed 
      comparable efficacy in ES-SCLC patients with brain metastases, with no 
      significant differences in OS (HR, 1.505; 95% CI, 0.684-3.311; P=0.309) and PFS 
      (HR, 0.649; 95% CI, 0.356-1.182; P=0.157). CONCLUSIONS: PD-1 and PD-L1 inhibitors 
      might achieved comparable survival benefit and safety in ES-SCLC patients. A 
      longer PFS was observed in patients treated with PD-1 inhibitors in the 
      first-line treatment, and the PD-1 inhibitor camrelizumab might have achieved a 
      better PFS compared with other ICIs.
CI  - 2022 Journal of Thoracic Disease. All rights reserved.
FAU - Yang, Guanghui
AU  - Yang G
AD  - Cheeloo College of Medicine, Shandong University, Jinan, China.
AD  - Department of Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, 
      Shandong University, Qingdao, China.
FAU - Sun, Hongfu
AU  - Sun H
AD  - Cheeloo College of Medicine, Shandong University, Jinan, China.
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Sun, Nini
AU  - Sun N
AD  - Radiotherapy Center, Xi'an International Medical Center Hospital, Xi'an, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Wang, Zhongtang
AU  - Wang Z
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Zhang, Huawei
AU  - Zhang H
AD  - Department of Ultrasound in Medicine, Provincial Hospital Affiliated to Shandong 
      First Medical University, Jinan, China.
FAU - Liu, Chengxin
AU  - Liu C
AD  - Cheeloo College of Medicine, Shandong University, Jinan, China.
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC9840043
OTO - NOTNLM
OT  - Extensive-stage small-cell lung cancer (ES-SCLC)
OT  - immune-checkpoint inhibitors (ICIs)
OT  - programmed cell death 1 (PD-1) inhibitors
OT  - programmed cell death ligand 1 (PD-L1) inhibitors
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-22-1682/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/01/18 06:00
MHDA- 2023/01/18 06:01
PMCR- 2022/12/01
CRDT- 2023/01/17 01:46
PHST- 2022/11/02 00:00 [received]
PHST- 2022/12/19 00:00 [accepted]
PHST- 2023/01/17 01:46 [entrez]
PHST- 2023/01/18 06:00 [pubmed]
PHST- 2023/01/18 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - jtd-14-12-4925 [pii]
AID - 10.21037/jtd-22-1682 [doi]
PST - ppublish
SO  - J Thorac Dis. 2022 Dec;14(12):4925-4937. doi: 10.21037/jtd-22-1682.